Suppression of the high endogenous levels of plasma FSH in infertile men are associated with improved Sertoli cell function as reflected by elevated levels of plasma inhibin B.
BACKGROUND
In vitro continuous stimulation of Sertoli cells with FSH leads to a desensitization of these cells to FSH action. To evaluate the presence of a desensitization of FSH receptor on Sertoli cells in vivo, we performed a controlled clinical study in 97 men affected by severe oligozoospermia.


METHODS
On the basis of FSH and inhibin B plasma concentrations, these subjects were divided into three groups: group A, 33 subjects with high FSH and low inhibin B plasma levels; group B, 32 subjects with high FSH plasma levels and inhibin B concentrations at the lower limit of the normal range; and group C, 32 subjects with normal FSH and inhibin B plasma levels. Patients with high FSH plasma levels (groups A and B) were prospectively randomized into two subgroups, called A1, A2, B1 and B2. Patients of groups A1 and B1 were treated with a GnRH agonist, leuprolide acetate, to induce a hypogonadotrophic state and then were treated with recombinant human FSH (r-hFSH; 100 IU/day) and hCG (2000 IU/twice a week) for 2 months. Subjects of groups A2, B2 and C were treated only with r-hFSH for the same period.


RESULTS
In patients of group A1, inhibin B remained unmodified during the whole period of study, whereas in subjects of group B1, we observed a significant reduction of this hormone during the hypogonadotrophic period and then an increase of inhibin B plasma levels that were higher that those observed before therapy. In patients of groups A2 and B2, FSH treatment did not induce a significant increase in inhibin B concentrations. In patients of group C, FSH induced a significant increase in inhibin B plasma levels.


CONCLUSIONS
In infertile men, suppression of the high endogenous levels of plasma FSH associated with much lower exogenous FSH levels is able to evoke higher inhibin B production, which may indicate improved Sertoli cell function and the possibility that this could have a positive effect on spermatogenesis.
Foresta
C
C
Centre for Male Gamete Cryopreservation, Department of Medical and Surgical Sciences, Via Ospedale 105, 35128 Padova, Italy. carlo.foresta@unipd.it
Bettella
A
A
Spolaore
D
D
Merico
M
M
Rossato
M
M
Ferlin
A
A
D000328:Adult; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D005640:Follicle Stimulating Hormone / Q000037:antagonists & inhibitors* / Q000097:blood* / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D007248:Infertility, Male / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D007265:Inhibins / Q000097:blood*; D016729:Leuprolide / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009994:Osmolar Concentration; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D012708:Sertoli Cells
D006063:Chorionic Gonadotropin; D011994:Recombinant Proteins; C422364:inhibin B; D007987:Gonadotropin-Releasing Hormone; D007265:Inhibins; D005640:Follicle Stimulating Hormone; D016729:Leuprolide